Information Provided By:
Fly News Breaks for March 2, 2020
Mar 2, 2020 | 07:50 EDT
JPMorgan analyst Eric Joseph initiated coverage of Beam Therapeutics with an Overweight rating and $31 price target. With its proprietary base-editing gene therapy platform, Beam has "multiple shots on goal" with either first- or best-in-class potential across a diverse set of rare disease and oncology applications, Joseph tells investors in a research note.
News For BEAM From the Last 2 Days
There are no results for your query BEAM